Vanda Pharmaceuticals (VNDA) Capital Expenditures Growth (3y) (2014 - 2026)
Vanda Pharmaceuticals (VNDA) Capital Expenditures Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Vanda Pharmaceuticals | 310.98 Mn | 108.67 Mn | 48.56 Mn | 63.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.03% |
| Dec 31, 2025 | -27.07% |
| Sep 30, 2025 | 2.85% |
| Jun 30, 2025 | 15.71% |
| Mar 31, 2025 | 79.81% |
| Dec 31, 2024 | 16.89% |
| Sep 30, 2024 | 162.56% |
| Jun 30, 2024 | -28.70% |
| Mar 31, 2024 | -62.24% |
| Dec 31, 2023 | -36.02% |
| Sep 30, 2023 | -53.96% |
| Jun 30, 2023 | -36.02% |
| Mar 31, 2023 | -48.48% |
| Dec 31, 2022 | 56.97% |
| Sep 30, 2022 | -20.45% |
| Jun 30, 2022 | -9.92% |
| Mar 31, 2022 | -42.43% |
| Dec 31, 2021 | 82.63% |
| Sep 30, 2021 | -27.52% |
| Jun 30, 2021 | 58.39% |